Castellnou Solène, Bretones Patricia, Abeillon Juliette, Moret Myriam, Perrin Pauline, Chikh Karim, Raverot Véronique
Hospices Civils de Lyon, Groupement Hospitalier Est, Fédération d'Endocrinologie, Bron, France.
Service d'Endocrinologie Pédiatrique, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
Eur Thyroid J. 2021 Apr;10(2):174-178. doi: 10.1159/000509015. Epub 2020 Aug 5.
Maternal TSH receptor antibodies (TRAbs) can cross the placenta and affect fetal and neonatal thyroid function. Maternal TSH receptor-blocking antibodies (TBAbs) are a rare cause of congenital hypothyroidism.
Following the discovery of a highly elevated TSH on her neonatal screening test, a 10-day-old girl with no familial history of thyroid disorder was referred to the pediatric endocrinology unit. Hypothyroidism was confirmed with a highly elevated TSH (817 mIU/L, reference range 0.4-3.1) and very low levels of FT4 (1.8 pmol/L, reference range 12-22). Anti-TPO antibodies were at 81 IU/mL (reference range <34), TRAbs at 1.7 IU/L (reference range <1.75), and thyroglobulin at 9.4 µg/L (reference range 3.5-77). The thyroid appeared normal on ultrasonography, and no radioiodine uptake was seen on the scintigraphy after the perchlorate discharge test. Concomitantly, a severe maternal hypothyroidism was discovered (TSH 224 mIU/L). The maternal ultrasound appeared normal, anti-TPO antibodies were moderately elevated, and TRAbs were at 3.2 IU/L. TBAbs activity was measured in the mother and her daughter, and a very high and similar blocking activity was observed in both patients (TBAbs 89%, reference range <10%). L-thyroxine treatment was introduced in the newborn and was successfully discontinued at 6.5 months of age, as the TBAbs activity decreased.
We report herein a case of transient congenital hypothyroidism with a normal neonatal TRAbs level. In case of maternal TBAbs, similar activity of maternal TBAbs must be expected in the neonate, independently of the neonatal level of TRAbs.
母体促甲状腺激素受体抗体(TRAbs)可穿过胎盘并影响胎儿及新生儿的甲状腺功能。母体促甲状腺激素受体阻断抗体(TBAbs)是先天性甲状腺功能减退症的罕见病因。
一名10日龄女童在新生儿筛查试验中发现促甲状腺激素(TSH)高度升高,其家族无甲状腺疾病病史,遂被转诊至儿科内分泌科。经检查,促甲状腺激素显著升高(817 mIU/L,参考范围0.4 - 3.1)且游离甲状腺素(FT4)水平极低(1.8 pmol/L,参考范围12 - 22),确诊为甲状腺功能减退症。抗甲状腺过氧化物酶(TPO)抗体为81 IU/mL(参考范围<34),TRAbs为1.7 IU/L(参考范围<1.75),甲状腺球蛋白为9.4 μg/L(参考范围3.5 - 77)。超声检查显示甲状腺外观正常,过氯酸盐释放试验后的闪烁扫描未见放射性碘摄取。与此同时,发现其母亲患有严重的甲状腺功能减退症(TSH 224 mIU/L)。母亲的超声检查结果正常,抗TPO抗体中度升高,TRAbs为3.2 IU/L。对母亲和女儿进行了TBAbs活性检测,发现两名患者的阻断活性都非常高且相似(TBAbs 89%,参考范围<10%)。新生儿开始接受左甲状腺素治疗,随着TBAbs活性降低,在6.5月龄时成功停药。
我们在此报告一例新生儿TRAbs水平正常的短暂性先天性甲状腺功能减退症病例。在母体存在TBAbs的情况下,无论新生儿TRAbs水平如何,预计新生儿体内母体TBAbs的活性相似。